Objective: The aim of this study was to determine whether the insertion (I) /deletion (D) polymorphism within intron 16 of angiotensin-converting enzyme (ACE) confers susceptibility to systemic lupus erythematosus (SLE) and lupus nephritis (LN). Methods: A meta-analysis was conducted on the associations between the ACE I/D polymorphism and SLE and LN. Results: A total of 1907 patients with SLE and 1842 controls in 18 comparative studies were included in this metaanalysis. The analysis showed a significant association between SLE and the DD genotype (recessive effect) of the ACE polymorphism (odds ratio [OR] 1.383, 95% confidence interval [CI] 1.065-1.797, p = 0.015). Stratification by ethnicity indicated a marginal association between the DD genotype and SLE in Europeans (OR 1.210, 95% CI 0.964-1.519, p = 0.099; I 2 = 0%). Meta-analysis also revealed a trend toward to an association between SLE and the ACE polymorphism using the allelic or additive models in Europeans. Furthermore, meta-analysis of the DD+ID genotype showed a significant association with LN (OR 0.582, 95% CI 0.425-0.797, p = 0.001; I 2 = 0%). Conclusion: This meta-analysis demonstrates a strong association between DD genotype and SLE in overall study and a marginal association between SLE and the ACE D/I polymorphism in Europeans, and suggests that this polymorphism might confer susceptibility to LN.
Introduction
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by intense inflammation and multiple organ damage, and in which immune regulation is disrupted. Furthermore, lupus nephritis (LN) remains a predominant cause of morbidity and mortality in SLE. 1, 2 Moreover, significant familial aggregation and convincing evidence of multiple genetic linkages demonstrate that the etiology of SLE is genetic in nature. 3 Angiotensin-converting enzyme (ACE) activates angiotensin I into angiotensin II and inactivates bradykinin via the kallikrein-kininogen system. 4 Angiotensin II is the main effector molecule of the renin angiotensin system (RAS), is pleiotropic, and a mediator of the development and progression of renal disease. 5 It is also a potent pro-inflammatory modulator that augments and perpetuates immune responses. 5 The ACE gene, located on chromosome 17q23, contains an insertion (I)/deletion (D) polymorphism within intron 16 that involving the presence or absence of a 287 bp repeat sequence, 6 and the DD genotype has been reported to be associated with approximately twofold higher tissue and plasma concentrations of ACE than the II genotype. 6 Thus, it seems that the D allele could play a role in the pathogenesis of SLE.
In addition, the ACE I/D polymorphism has been associated with SLE by some authors, but by no means by all, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] possibly due to small sample sizes, low statistical power, and/or clinical heterogeneity. Therefore, in order to overcome the limitations of individual studies, resolve inconsistencies, and reduce the likelihood that random errors are responsible for false-positive or false-negative associations, we turned to meta-analysis. [21] [22] [23] The aim of the present study was to determine whether the ACE I/D polymorphism confers susceptibility to SLE and LN.
Methods

Identification of eligible studies and data extraction
We performed a search of studies that examined associations between the ACE I/D polymorphism and SLE using the MEDLINE citation database to identify available articles in which the ACE I/D polymorphism was analyzed in patients with SLE. Combinations of keywords, such as, "angiotensin-converting enzyme," "ACE," "polymorphism," "systemic lupus erythematosus," and "SLE" were entered as Medical Subject Heading (MeSH) components and as text words. References in identified studies were also investigated to identify additional studies not indexed by MEDLINE. Genetic association studies that determined the distributions of the ACE I/D polymorphism in SLE and in normal controls were included. The following information was extracted from each identified study: author, year of publication, ethnicity of the study population, demographics, number of cases and controls, and the frequencies of the genotypes and alleles of the ACE I/D polymorphism.
Evaluation of publication bias
Funnel plots are used to detect publication bias, but they require a range of studies of varying sizes and subjective judgments, and thus we evaluated publication bias using Begg adjusted rank correlation test and Egger's linear regression test, 24 which measures funnel plot asymmetry on a natural logarithm scale of odds ratios (ORs). The chisquare test was used to determine if observed genotype frequencies in controls conformed to Hardy-Weinberg (HW) expectations.
Evaluations of statistical associations
We performed meta-analyses using: 1) allelic contrast (D vs. I); and 2) the recessive (DD vs. ID+II), 3) the dominant (DD+ID vs. II), and 4) the additive models (DD vs. II). Point estimates of risks, ORs, and 95% confidence intervals (CI) were estimated for each study. In addition, within-and between-study variations and heterogeneities were assessed using Cochran's Q-statistic. This heterogeneity test assesses the null hypothesis that all studies evaluated the same effect. The effect of heterogeneity was quantified using I 2 , which ranges between 0 and 100% and represents the proportion of between study variability attributable to heterogeneity rather than chance. 25 I 2 values of 25%, 50%, and 75% were nominally defined as low, moderate, and high estimates. The fixed effects model assumes that a genetic factor has a similar effect on SLE susceptibility across all studies investigated, and that observed variations among studies are caused by chance alone. 26 The random effects model assumes that different studies show substantial diversity and assesses both within-study sampling error and between-study variance. 27 When study groups are homogeneous, the two models are similar, but if this is not the case the random effects model usually provides wider CIs than the fixed effects model. The random effects model is best used in the presence of significant between-study heterogeneity. 27 Statistical manipulations were undertaken using a Comprehensive Meta-Analysis computer program (Biosta, Englewood, NJ, USA). The power of each study was computed as the probability of detecting an association between the ACE polymorphism and SLE using a significance level of 0.05, assuming an OR of 1.5 (small effect size). Power analysis was performed using the statistical program G*Power (http://www.psycho.uni-duesseldorf.de/aap/projects/ gpower).
Results
Studies included in the meta-analysis
Twenty-six studies were identified by electronic and manual searches and 20 were selected for a full-text review based on title and abstract details. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [28] [29] [30] [31] Five of these 20 studies were excluded because one did not include the ACE polymorphism, 28 two contained duplicated data, 10,31 and two were not case-control studies. 29, 30 One of the eligible studies contained data on three different ethnic groups 14 and two included data on two different groups, 11, 19 and these were treated independently. Thus, a total of 18 separate comparisons were considered in the meta-analysis, and in total, these contained 1907 patients and 1842 controls ( Table 1) . [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] These 18 studies encompassed six European, four Asian, three African, and one Egyptian, one Pakistani, one Kuwaiti, one Brazilian, and one unknown population. Eighteen studies examined the ACE D/I polymorphism in SLE and six studies in LN. The statistical powers of the studies ranged from 9.57-60.6%. No study had a statistical power exceeding 80%. The mean frequency of the D allele was 55.6% in SLE and 52.0% in controls. Selected details of the individual studies are summarized in Table 1 .
Heterogeneity and publication bias
The distributions of genotypes of the ACE polymorphism in 17 of the 18 control groups were consistent with the HW equilibrium. Deviation from the HW equilibrium among controls implies the possibility of selection bias or genotyping errors. However, when the affected study was excluded results were not substantially affected. 7 No between-study heterogeneity was found during the analysis of the D allele, the DD genotype, and the DD vs. the II genotype in Europeans, or during the analysis of the DD genotype and the DD vs. the II genotype in Africans. Thus, these metaanalyses were performed using a fixed effects model, and the others were performed using a random effects model ( Table 2) . Publication bias causes a disproportionate number of positive studies, and poses a problem for meta-analyses, but Begg adjusted rank correlation test and Egger's regression test showed no evidence of publication bias in this meta-analyses (Begg adjusted rank correlation test and Egger's regression test p-values >0.1).
Meta-analysis of the association between the ACE I/D polymorphism and SLE
Meta-analysis showed a significant association between SLE and the DD genotype (recessive effect) (OR 1.383, 95% CI 1.065-1.797, p = 0.015) (Table 2, Figure 1 ), but between-study heterogeneity was observed (I 2 = 65.0%). Stratification by ethnicity indicated a marginal association between the DD genotype and SLE in Europeans without between-study heterogeneity (OR 1.210, 95% CI 0.964-1.519, p = 0.099; I 2 = 0%) ( Table 2) . Meta-analysis also revealed marginal associations between SLE and the I/D polymorphism using the allelic and additive models in Europeans. However, meta-analysis showed no association between SLE and the I/D polymorphism using the allelic, recessive, dominant, or additive models in Asians or Africans ( Table 2) .
Meta-analysis of the association between the ACE I/D polymorphism and LN
Six studies were included in the meta-analysis of the association between the ACE I/D polymorphism and LN. Metaanalysis of the D allele, the DD genotype, and the DD vs. the II genotype showed no association between LN and the I/D polymorphism, but meta-analysis of the DD+ID genotype showed a significant association with LN without between-study heterogeneity (OR 0.582, 95% CI 0.425-0.797, p = 0.001; I 2 = 0%) (Table 3, Figure 2 ).
Discussion
ACE is expressed in a wide range of tissues, including the kidneys, heart, lungs, vascular endothelium, and testes. ACE plays an important role in RAS and angiotensin II conversion, increases vascular smooth muscle cell contraction, and affects smooth muscle proliferation, monocyte adhesion, platelet adhesion, and aggregation. Angiotensin II also acts as a potent pro-inflammatory modulator. 5, 32 The ACE I/D polymorphism is located in an intron of the ACE gene, and is in strong linkage disequilibrium with genetic factors that influence serum ACE levels. 6 In fact, the ACE I/D polymorphism accounts for approximately one-half of the variance shown by ACE plasma levels in man. In addition, the I/D polymorphism has been studied in several diseases and conditions, such as Alzheimer's disease, myocardial infarction, cerebral infarct, hypertension, and diabetic nephropathy, and these studies have also identified associations between disease susceptibilities and the DD genotype and D allele. [33] [34] [35] [36] [37] Based on considerations of biological function and chromosomal location, ACE is considered a possible causative gene of SLE. However, previous studies on the ACE I/D polymorphism in SLE have produced controversial results. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Such discrepancies could be due to clinical heterogeneity, ethnic differences, real genetic heterogeneity, small sample sizes, or low statistical power, although actual causes have not been determined. Meta-analysis is a useful tool for summarizing inconsistent results from different studies because it increases sample size and statistical power. 21, 38 Thus, we undertook the present study to clarify the roles played by the ACE I/D polymorphism in SLE and LN. In a previous meta-analysis, which included 2962 subjects, we found no association between the ACE I/D polymorphism and SLE or LN. 39 In the present study, we updated this previous analysis and included four additional studies. 7-10 Accordingly, the present meta-analysis included 3749 subjects (1907 cases and 1842 controls) from 18 comparative studies that explored the associations between the ACE I/D polymorphism and SLE or LN, and in the present study we found a significant association between the DD genotype and SLE in all study subjects. To rule out the effect of ethnic heterogeneity, we compared the ACE I/D polymorphism in each ethnic group. Analysis revealed marginal associations between the DD genotype, the D allele, and the DD vs. the II genotype and SLE in Europeans, but no association between the polymorphism and SLE in Asians or Africans. In addition, the DD+ID genotype was found to be significantly associated with LN. Thus, this meta-analysis suggests the ACE I/D polymorphism plays a role in SLE susceptibility in Europeans and that it might also contribute to the development of LN.
The present study differs from a previous meta-analysis by Zhou et al. 40 There was a difference in results on association between ACE polymorphism and SLE in Europeans and Asians in the present study and recently published study by Zhou et al. The difference may be due to inclusion of several additional Chinese studies into meta-analysis by Zhou et al. Three studies by Huang et al., 41 Lv et al., 42 and Hussain et al. 43 were included only in Zhou et al.'s study, 40 while two studies by Abbas et al. 7 and Rabbani et al. 8 were included only in the present analysis. Another difference between the present study and the previous meta-analysis is the association between ACE polymorphism and LN, such as no association of the DD genotype was found presently, and Zhou et al. demonstrated that the DD genotype was associated with the risk of LN. 40 The difference may be also due to the difference of studies included in each meta-analysis for LN. Our meta-analysis included six studies, and the study by Zhou et al. included seven studies. Five studies were included in both meta-analysis studies. 9, 10, 14, 17, 20 However, a study by Abbas et al. 7 was only included in our meta-analysis, while a study by Huang et al. 41 and a study by Hussain et al. 43 were included only in the meta-analysis by Zhou et al. 40 The present study has some limitations that should be considered. First, heterogeneity and confounding factors may have distorted the analysis. Publication bias may also have affected the analysis, because studies that produced negative results may not have been published or may have been missed, despite our performing Begg adjusted rank correlation test and Egger's regression test. Second, any polymorphism in ACE capable of affecting SLE activity could also be associated with SLE severity. However, the limited amount of data available prevented meta-analysis on the association between the ACE polymorphism and disease severity, with the exception of our analysis of the relation between the ACE I/D polymorphism and LN. Third, the number of subjects enrolled in most of the included studies was small, and this may have affected the statistical power of this meta-analysis. Fourth, we included data from European, Asian, and African patients in our ethnic-specific meta-analysis, and thus our ethnicity associated results are applicable to only these ethnic groups.
In conclusion, this meta-analysis of 3749 subjects provides evidence of a strong association between DD genotype and SLE in studies overall, and a marginal association between SLE and the ACE I/D polymorphism in Europeans, but no evidence of a similar association in Asians or Africans. Furthermore, this analysis suggests that the ACE I/D polymorphism is associated with the development of LN. Larger-scale studies in populations with different ethnicities are required to explore relations between polymorphisms of the ACE gene and the pathogenesis of SLE.
